ADVERTISEMENT
Poster
1591793
An Updated Meta-Analysis of the Clinical Utility of Combinatorial Pharmacogenomic Testing for Adult Patients with Depression
Psych Congress 2023
This work was sponsored by Myriad Genetics, Inc.
Introduction: Previous studies demonstrate that combinatorial pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. An updated meta-analysis was performed to investigate the clinical utility of combinatorial PGx testing. Prospective studies utilizing a commercially available combinatorial PGx test were meta-analyzed to compare PGx guided care to unguided care in patients with MDD.
Methods: This updated meta-analysis builds upon a previously conducted meta-analysis, which included 1,556 patients from 4 combinatorial PGx studies. Additional studies were identified using PRISMA guidelines. A random-effects model was used to calculate the pooled relative risk ratio (RR) of response and remission.
Results: Overall, 3,532 patients were included from six studies, with outcomes evaluated at week 8 or week 10. Patient outcomes were significantly improved for patients with MDD whose care was guided by the combinatorial PGx test results compared to unguided care (response RR = 1.30, 95% CI: 1.16–1.47, p
Sign Up
Psych Congress Network Newsletter
